Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Jun Gong(Cedars-Sinai Medical Center), Keith T. Flaherty(Cancer Research Center), Lyndsay N. Harris(National Institutes of Health), Peter J. O’Dwyer(University of Pennsylvania), Larry Rubinstein(National Cancer Institute), David R. Patton(National Cancer Institute), Lisa M. McShane(National Cancer Institute), Carlos L. Arteaga(The University of Texas Southwestern Medical Center), Ajjai Alva(Michigan Medicine), Heather H. Cheng(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Barbara A. Conley(National Cancer Institute), James V. Tricoli(National Cancer Institute), Robert J. Gray(University of Glasgow), Stanley R. Hamilton(City of Hope), S. Percy Ivy(National Cancer Institute), Edith P. Mitchell(Thomas Jefferson University Hospital), Zihan Wei(The People's Hospital of Guangxi Zhuang Autonomous Region), P. Mickey Williams(Leidos (United States)), Alain C. Mita(Cedars-Sinai Medical Center), Victoria Wang(Dana-Farber Cancer Institute), Alice P. Chen(National Cancer Institute)
Cited by 16
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k